Bristol-Myers Squibb BMY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 281.3%0.0pp | 281.3%0.0pp | 281.3%-5.4pp | 286.7%-5.1pp | 291.8%-5.2pp | |
| Net margin | 52.5%+3.8pp | 48.7%+33.3pp | 15.4%+27.7pp | -12.3%+24.5pp | -36.8%+24.7pp | |
| Returns | ||||||
| Return on equity | 141.7%+7.3pp | 134.4%+79.9pp | 54.5%+64.9pp | -10.4%+55.6pp | -66%+57.0pp | |
| Return on invested capital | 44.5%+4.2pp | 40.2%+27.2pp | 13%+22.0pp | -9%+18.5pp | -27.5%+18.1pp | |
| Efficiency | ||||||
| Asset turnover | 2.1×0.0× | 2×0.0× | 2×0.0× | 2×0.0× | 2×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.1×+0.1× | 5×0.0× | 5×0.0× | 5×+0.1× | 4.9×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 10.3×-0.6× | 10.9×-0.6× | 11.5×-0.3× | 11.7×-0.3× | 12×-0.5× | |
| Net debt / EBITDA | 10.9×-0.1× | 11×-36.3× | 47.3×-10.1× | 57.4×-10.0× | 67.4×-8.8× | |
| Valuation | ||||||
| Market capitalization | $421.15B-0.1% | $421.42B-1.2% | $426.32B-3.0% | $439.42B+2.7% | $427.9B+3.5% | |
| Price / earnings | 67.2×-6.2× | 73.4×— | —— | —— | —— | |
| Price / sales | 8.8×-0.1× | 8.8×-0.1× | 8.9×-0.3× | 9.2×+0.2× | 9×+0.2× | |
| Price / book | 22.6×-1.0× | 23.5×-1.1× | 24.6×-1.2× | 25.8×+0.5× | 25.2×+0.5× | |
| EV / EBITDA | 43.1×+0.4× | 42.7×-138× | 180.4×-34.7× | 215.1×-25.9× | 241×-27.2× | |
| Dividend yield | 19.3%+0.1pp | 19.2%+0.4pp | 18.8%+0.9pp | 18%-0.5pp | 18.5%-0.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Bristol-Myers Squibb's ratios come from?
- Every ratio is computed from Bristol-Myers Squibb's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
